Vyluma Meets with FDA on Atropine Sulfate Ophthalmic Solution 0.01% Under Development to Treat Pediatric Myopia

Posted 2024-06-18, Nasdaq Globe Newswire Headlines

Vyluma Discusses Response to FDA’s Questions and Clarifies Regulatory Pathway for its 505(b)(2) NDA, NVK002 to slow the progression of myopia in children. ...... read full story

Ask about this article

Answer for your question of the article will be displayed here ...